Virginia is currently home to 1825 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Richmond, Charlottesville, Norfolk and Fairfax. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Effects of Obesity and Intensity of Exercise on Ghrelin Levels
NCT04581980
Recruiting
This study is investigating the effect of different intensities of exercise on levels of the hormone, ghrelin. In addition, we will be examining the relationship between any exercise induced changes in ghrelin and insulin sensitivity, obesity, and vascular function.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
05/08/2023
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Obesity, Insulin Resistance, Cardiovascular Risk Factor
Register for Updates
Low-Intensity Focused Ultrasound for Cocaine Use Disorder
NCT05857852
Recruiting
This study aims to understand the role of Low-Intensity Focused Ultrasound on craving levels for cocaine as evidenced by diagnostic imaging of the dorsal anterior insula (dAI) and subjective ratings. Data analysis will serve to show if 1) LIFU is safe and effective and to 2) examine the effects of LIFU on dAI BOLD activity and craving in response to cocaine cue-exposure. The study will screen 60 individuals with Cocaine Use Disorder (CUD) to arrive at 30 enrolled subjects, based on a 2:1 screen/... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/04/2023
Locations: UVA Center for Leading Edge Addiction Research, Charlottesville, Virginia
Conditions: Cocaine Use Disorder, Cocaine Dependence, Cocaine Abuse, Ultrasound
Register for Updates
Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
NCT03945162
Recruiting
This is a phase II, open-label, single-arm, multi-center Study conducted in Canada and the United States. Patients with NMIBC CIS (with or without resected papillary disease (Ta, T1)) that are considered Bacillus Calmette-Guerin ("BCG")-Unresponsive or who are intolerant to BCG therapy. BCG-Unresponsive is at least one of the following: At least five of six doses of an initial induction course plus at least two of three doses of maintenance therapy; or, at least five of six doses of an initial i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/27/2023
Locations: Site 02-009 - Virginia Urology, Richmond, Virginia
Conditions: Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
Register for Updates
Platelet Adhesion in the Pathobiology of Aortic Stenosis
NCT05550896
Recruiting
Aortic stenosis (AS) is a serious and common condition that affects 2-3% of the population \>65 years of age in Western countries. It is also responsible for extraordinarily high healthcare expenditures, estimated to be over $6 billion annually,2 in part because the primary treatment for severe AS is aortic valve replacement (AVR) which is resource-intensive. Valve abnormalities are frequently recognized before AS becomes severe, or before there is need for guideline-directed procedural interven... Read More
Gender:
ALL
Ages:
25 years and above
Trial Updated:
04/18/2023
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Aortic Valve Stenosis
Register for Updates
A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AML
NCT05503355
Recruiting
An open label multi centre study to assess the safety and efficacy of BST-236 in combination with venetoclax in adult patients unfit for standard therapy with newly diagnosed Acute Myeloid Leukemia (AML) Part 1 of the study will define the maximal tolerate dose of the combination treatment, while part 2 will expend the chosen dose, to assesses efficacy and safety of this combination. All patients will receive 2 induction courses with both BST-236 and venetoclax, responding patients will then be... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
04/02/2023
Locations: University of Virginia Cancer Center, Charlottesville, Virginia
Conditions: AML, Adult
Register for Updates
HR-EGG in Medically Refractory Gastroparesis
NCT05789511
Recruiting
The goal of this observational study is to utilize a novel high resolution electrogastrography device to gauge if identification of gastric dysarrythmias can reliably identify patients that will respond to or will require definitive pyloric interventions such as a G-POEM procedure in patients with medically refractory gastroparesis Aims: 1. Assess for the presence of gastric dysarrythmias in lung transplantation population as compared to alternative etiologies of gastroparesis 2. Assess if pre... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2023
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Gastroparesis, Lung Transplant; Complications
Register for Updates
Ultrasound Cavitation Therapy for CLI
NCT05749250
Recruiting
In this study, we will explore how ultrasound exposure of ultrasound contrast agents, which produces beneficial shear-mediated bioeffects, can be used to treat patients with severe non-healing ulcers secondary to peripheral arterial disease (PAD). The primary outcome measure is whether ultrasound exposure to microbubble contrast agents in the inflow artery and at the wound site can accelerate wound healing. A secondary outcome measure is whether cavitation-related changes occur in tissue perfusi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2023
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Peripheral Arterial Disease
Register for Updates
Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma
NCT03787602
Recruiting
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Merkel Cell Carcinoma (MCC) who have failed treatment with at least one anti-PD-1 or anti-PD-L1 immunotherapy or in combination with avelumab in MCC patients who are anti-PD-1 or anti-PD-L1 treatment naïve. Inhibition of MDM2 is a novel mechanism of action in MCC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2023
Locations: Inova Health Care Services, Fairfax, Virginia
Conditions: Merkel Cell Carcinoma
Register for Updates
Contrast-enhanced Spectral Mammography (CESM) Breast Cancer Screening
NCT04904757
Recruiting
The purpose of this study is to evaluate how well women may adopt a Contrast-enhanced Spectral Mammography (CESM) as their yearly breast screening test compared to the standard 2-D or 3-D mammogram.
Gender:
FEMALE
Ages:
Between 40 years and 69 years
Trial Updated:
11/16/2022
Locations: UVA Breast Care Center, Charlottesville, Virginia
Conditions: Mammographic Breast Density, Mammography
Register for Updates
A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors
NCT04843709
Recruiting
The objective of this study is to evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of MRG004A in patients with Tissue Factor positive advanced or metastatic solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/06/2022
Locations: Virginia Cancer Specialists, Fairfax, Virginia
Conditions: Advanced or Metastatic Solid Tumors
Register for Updates
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer
NCT05486143
Recruiting
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy. Condition or disease: Breast Cancer Intervention/treatment: Drug: Gedatolisib Drug: Palbociclib Drug: Fulvestrant Drug: Alpelisib Phase 3
Gender:
All
Ages:
18 years and above
Trial Updated:
08/02/2022
Locations: Fort Belvoir Community Hospital, Fort Belvoir, Virginia
Conditions: Breast Cancer
Register for Updates
A Study in Patients With Advanced Cancers
NCT05320588
Recruiting
A first-in-human study using BIO-106 as a single agent and in combination with pembrolizumab in advanced cancers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2022
Locations: NEXT Oncology Virginia, Fairfax, Virginia
Conditions: Advanced Cancer, Advanced Solid Tumor, Cancer, Oncology
Register for Updates